Search
03/05/2023
The ATLAS ASMA Study: Assessing the Impact of Asthma on Patients' Life-The Spanish Patients' Perspective
Dominguez-Ortega J., Plaza V., Nieto A., Romero J.D., Ancochea J., Mejia N., Pastor M., Blanco-Aparicio M.. The ATLAS ASMA Study: Assessing the Impact of Asthma on Patients' Life-The Spanish Patients' Perspective. Journal of Asthma and Allergy. 2023; 16DOI:10.2147/JAA.S404525. PMID:37163179. IF:3.700(Q1/3D).
17/04/2023
Residual pulmonary infiltrates, symptoms and diffusion impairment at 1-year after severe COVID-19 infection have different associated factors
Menendez, R, Mendez, R, Latorre, A, Gonzalez-Jimenez, P, Peces-Barba, G, Molina, M, Espana, PP, Garcia, E, Consuegra-Vanegas, A, Pando-Sandoval, A, Panadero, C, Figueira-Goncalves, JM, de la Rosa, D, Sibila, O, Martinez-Pitarch, MD, Toledo, N, Cejudo, P, Almonte-Batista, W, Macias-Paredes, A, Badenes, D, Perez-Rodas, EN, Lazaro, J, Quiros, S, Cordovilla, R, Cano-Pumarega, I, Torres, A. Residual pulmonary infiltrates, symptoms and diffusion impairment at 1-year after severe COVID-19 infection have different associated factors. JOURNAL OF INTERNAL MEDICINE. 2023; 294(1)DOI:10.1111/joim.13642. PMID:37038609. IF:9.000(Q1/1D).
03/04/2023
The role of precision medicine in bronchiectasis: emerging data and clinical implications
Oscullo G., de la Rosa D., Clemente, MG, Giron R., Golpe R., Máiz L., Martinez-Garcia M.A.. The role of precision medicine in bronchiectasis: emerging data and clinical implications. Expert Review of Respiratory Medicine. 2023; 17(4)DOI:10.1080/17476348.2023.2205125. PMID:37077039. IF:2.900(Q2/4D).
01/04/2023
The immunoregulatory role of IL-35 in patients with interstitial lung disease
Osuna-Gomez, R, Barril, S, Mulet, M, Atenza, CZ, Millan-Billi, P, Pardessus, A, Brough, DE, Sabzevari, H, Semnani, RT, Castillo, D, Vidal, S. The immunoregulatory role of IL-35 in patients with interstitial lung disease. IMMUNOLOGY. 2023; 168(4)DOI:10.1111/imm.13596. PMID:36273280. IF:4.900(Q2/3D).
01/03/2023
What's New in the 2022 Consensus for Severe Asthma in Adults.
Alvarez-Gutiérrez FJ, Blanco-Aparicio M, Casas-Maldonado F, Plaza V, González-Barcala FJ, Carretero-Gracia JÁ, Castilla-Martínez M, Cisneros C, Diaz-Pérez D, Domingo-Ribas C, Martínez-Moragon E, Muñoz X, Padilla-Galo A, Perpiña-Tordera M, Soto-Campos G. What's New in the 2022 Consensus for Severe Asthma in Adults.. ARCHIVOS DE BRONCONEUMOLOGIA. 2023; 59(3)DOI:10.1016/j.arbres.2022.09.012. PMID:36243640. IF:8.700(Q1/1D).
01/03/2023
Evaluation of real-world mepolizumab use in severe asthma across Europe: the SHARP experience with privacy-preserving federated analysis
Kroes, JA, Alfonso-Cristancho, R, Bansal, AT, Berret, E, Bieksiene, K, Bourdin, A, Brussino, L, Canhoto, D, Cardini, C, Celik, G, Csoma, Z, Dahlen, B, Damadoglu, E, Eger, K, Gauquelin, L, Gemicioglu, B, Goksel, O, Graff, S, Heffler, E, Hofstee, HB, Howarth, P, Jakes, RW, Jaun, F, Kalinauskaite-Zukauske, V, Kopac, P, Kwon, N, Loureiro, CC, Garcia, VL, Masoli, M, Rezelj, MP, De Llano, LP, Popovic-Grle, S, Ramos-Barbon, D, Sousa, AS, Samitas, K, Schleich, F, Sirena, C, Skrgat, S, Zervas, E, Zichnalis, G, Bel, EH, Sont, JK, Hashimoto, S, Ten Brinke, A. Evaluation of real-world mepolizumab use in severe asthma across Europe: the SHARP experience with privacy-preserving federated analysis. Erj Open Research. 2023; 9(2)DOI:10.1183/23120541.00745-2022. PMID:37020841. IF:4.300(Q1/3D).